Family history influences the tumor characteristics and prognosis of breast cancers developing during postmenopausal hormone therapy

Näytä kaikki kuvailutiedot



Pysyväisosoite

http://hdl.handle.net/10138/303877

Lähdeviite

Fagerholm , R , Faltinova , M , Aaltonen , K , Aittomaki , K , Heikkila , P , Halttunen-Nieminen , M , Nevanlinna , H & Blomqvist , C 2018 , ' Family history influences the tumor characteristics and prognosis of breast cancers developing during postmenopausal hormone therapy ' , Familial Cancer , vol. 17 , no. 3 , pp. 321-331 . https://doi.org/10.1007/s10689-017-0046-2

Julkaisun nimi: Family history influences the tumor characteristics and prognosis of breast cancers developing during postmenopausal hormone therapy
Tekijä: Fagerholm, Rainer; Faltinova, Maria; Aaltonen, Kirsi; Aittomaki, Kristiina; Heikkila, Paivi; Halttunen-Nieminen, Mervi; Nevanlinna, Heli; Blomqvist, Carl
Tekijän organisaatio: Department of Obstetrics and Gynecology
Clinicum
Department of Oncology
Medicum
Kristiina Aittomäki / Principal Investigator
Department of Medical and Clinical Genetics
Department of Pathology
HUS Gynecology and Obstetrics
HUS Comprehensive Cancer Center
Teachers' Academy
Päiväys: 2018-07
Kieli: eng
Sivumäärä: 11
Kuuluu julkaisusarjaan: Familial Cancer
ISSN: 1389-9600
DOI-tunniste: https://doi.org/10.1007/s10689-017-0046-2
URI: http://hdl.handle.net/10138/303877
Tiivistelmä: Long term use of postmenopausal hormone therapy (HT) has been reported to increase breast cancer risk. On the other hand, observational studies suggest that breast cancers diagnosed during HT may have a more favorable prognosis. While family history is a risk factor for breast cancer, and genetic factors also influence prognosis, the role of family history in combination with HT use has been little studied. We investigated the relationship between HT, family history, and prognosis in 584 (267 exposed) familial and 952 (460 exposed) non-familial breast cancer cases, using three survival end points: death from breast cancer (BCS), distant disease free survival (DDFS), and local recurrence free survival (LRFS). Among non-familial cases, HT was associated with better BCS (HR 0.63, 95% CI 0.41-0.94; p = 0.025), and DDFS (HR 0.58, 95% CI 0.40-0.85; p = 0.005), with a consistent but not statistically significant effect in LRFS. This effect was not seen in familial cases (HR > 1.0), and family history was found to interact with HT in BCS (p((interaction)) = 0.0067) (BC-death) and DDFS (p((interaction)) = 0.0070). There was phenotypic heterogeneity between HT-associated tumors in familial and non-familial cases, particularly on estrogen receptor (ER) status, although the interaction between HT and family history appears to be at least partially independent of these markers (p = 0.0370 after adjustment for standard prognostic factors). If confirmed by further studies, our results suggest that family history should be taken into consideration in clinical counseling before beginning a HT regimen.
Avainsanat: Hormone replacement therapy
Breast cancer
Family history
Survival
Prognosis
Observational study
ESTROGEN PLUS PROGESTIN
REPLACEMENT THERAPY
BRCA2 MUTATIONS
FOLLOW-UP
WOMEN
RISK
MORTALITY
EXPRESSION
CARCINOMA
DIAGNOSIS
3122 Cancers
Vertaisarvioitu: Kyllä
Tekijänoikeustiedot: unspecified
Pääsyrajoitteet: openAccess
Rinnakkaistallennettu versio: publishedVersion


Tiedostot

Latausmäärä yhteensä: Ladataan...

Tiedosto(t) Koko Formaatti Näytä
Family_history_ ... _tumor_characteristics.pdf 751.8KB PDF Avaa tiedosto

Viite kuuluu kokoelmiin:

Näytä kaikki kuvailutiedot